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Abstract The relative safety of antidepressants during preg-
nancy has received substantial attention, but most syntheses
fail to account for mental illness effects. We aimed to evaluate
the literature comparing low birth weight (LBW) and
neurodevelopmental and neurobehavioural outcomes for chil-
dren whose mothers took antidepressants in pregnancy com-
pared to those whose mothers had common mental disorders,
or symptoms, but who did not take antidepressants during
pregnancy. A systematic review was conducted searching
PubMed, MEDLINE, PsycINFO and Embase in January
2015. A modified version of the Newcastle Ottawa Scale
was used to assess study quality. Eleven cohort studies were
included: four reporting a LBWoutcome (all with higher risk of
bias) and seven reporting a neurodevelopmental outcome (five
with higher risk of bias). We found only limited evidence of
gestational age-adjusted LBWin exposed children in two studies
which had a higher risk of bias and did not control for depressive
symptom severity. Only five (7.5%) neurodevelopmental out-
comes and one (12.5%) neurobehavioural outcome showed ev-
idence of a statistically significant effect, three out of four were
from studies with a higher risk of bias. There is little robust
evidence indicating a detrimental effect of antidepressant use
during pregnancy on LBW and neurodevelopmental and
neurobehavioural outcomes. More rigorous study designs are
needed.
Keywords Antidepressants . Low birth weight .
Neurodevelopment . Neurobehaviour . Pregnancy
Introduction
Depression and anxiety commonly occur in pregnancy, and
there exist a range of effective treatments (NICE 2015).
Psychological treatments are preferred for mild to moderate
uncomplicated episodes during pregnancy; however, more se-
vere or recurrent episodes are indications for pharmacological
treatment (Buist et al. 2005). Having an effective treatment in
place during pregnancy is important, as, in addition to the
distress and suffering they cause, common mental disorders
have been associated with increased risks of preterm delivery,
low birth weight (LBW) and neurodevelopmental or
neurobehavioural problems or delays in the offspring, such
as cognitive, emotional and behavioural development
(Agnafors et al. 2013; Grote et al. 2010; O’Connor et al.
2002).
The relative safety of antidepressant treatment during preg-
nancy has received substantial research attention. However,
among the numerous examples of previous systematic re-
views on the subject (Bromley et al. 2012; Fenger-Gron
et al. 2011; Gentile and Galbally 2011; Lattimore et al.
2005; McDonagh et al. 2014; Previti et al. 2014; Ross et al.
2013; Simoncelli et al. 2010; Udechuku et al. 2010), only one
(Ross et al. 2013) sought to assess the effects of antidepressant
exposure against being depressed but unexposed to antide-
pressants. This indicates that the vast majority of research,
and syntheses, has compared effects of exposure against
asymptomatic and unexposed women. Estimating effects
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compared to healthy unexposed women will tend to over-
estimate the risks of exposure relative to the actual clinical
problem, which is ‘Is it less harmful to the child [and the
mother] to continue with antidepressants, or remain medically
untreated during pregnancy?’ Accurate estimates from high-
quality research are necessary to ensure that clinical decisions
are properly informed.
Aims of the study
We sought to systematically evaluate the literature comparing
outcomes for children of women who took antidepressants
compared to those whose mothers had common mental disor-
ders, or symptoms, during pregnancy. We selected two groups
of outcomes: (1) LBW to provide current evidence given a
previous review (Ross et al. 2013) is now outdated and (2)
neurodevelopmental and neurobehavioural outcomes, for
which the evidence base is more sparse and no synthesis has
focused on reporting effects compared to a non-healthy con-
trol group. Our aims were twofold: (1) to report outcomes in
these two areas and (2) to examine in detail study methods and
potential areas of bias.
Materials and methods
Ethical approval was not sought as we reviewed previously
published studies.
Selection of studies
See Box 1 for the summary of the inclusion criteria. Included
studies were limited to articles published in peer-reviewed
journals and to papers published in English.
Studies were excluded if they:
& Reported a citation for which a full text was not available
or was not available in English
& Were abstracts
& Did not have a comparison group or lacked the outcomes
of interest
& Were conducted with non-human subjects
& Were meta-analyses, systematic reviews, literature re-
views or practice guidelines as the review was concerned
with original research (reference lists of relevant system-
atic reviews were searched for potentially relevant studies)
& Were case reports/case series as their samples are typically
small and the potential for bias is high
& Were cross-sectional
& Reported insufficiently defined assessments of
neurodevelopmental outcomes (e.g. the timing of outcome
assessment, measurement tools or units of measurement
were not reported)
Box 1: Inclusion criteria
Study design Randomised controlled trials and prospective (prospective
cohort) or retrospective (case-controlled studies,
retrospective cohort) observational studies
Population(s) Children whose mothers who took antidepressants while
pregnant
Exposure(s) Antidepressants
Comparators Children whose mothers were depressed or anxious and
non-exposed to antidepressants (not treated or under-
going psychological, or alternative treatments such as
light therapy, massage therapy, exercise or omega-3
fatty acid supplementation).
Outcomes At least one of the following outcomes:
LBWof infant/neonate is birth weight < 2.500 kg or small
for gestational age (SGA), defined as weight for gesta-
tion < 10th (or 5th) percentile or birth weight is lower
than 2 standard deviations below the mean value for the
gestational age.
Neurodevelopmental outcomes: emotional, behavioural,
IQ, speech and language, motor development, attention
and other forms of cognitive functioning and
neurodevelopmental diagnoses (autistic spectrum
disorder, attention deficit hyperactivity disorder and
pervasive developmental disorder) of infants and
young child that are measured at least 4 weeks after
birth, using rating scales carried out by trained staff.
Data sources
To identify all available studies meeting the inclusion criteria,
a computerised search was performed in PubMed,
MEDLINE, PsycINFO and Embase in January 2015 without
limits on year, language or study design. The search was con-
ducted by one author (IH) with support from an academic
liaison librarian. The Cochrane library and other databases
were searched to identify any relevant systematic reviews. A
manual search was also conducted on bibliographies of these
systematic reviews and others identified through the main
electronic search, and reference lists of included articles.
Search strategy
An example search strategy can be found in Appendix 1.
Screening and study selection
Screening was conducted by one author (IH). Titles and ab-
stracts were screened and the majority excluded based on
irrelevance to the search criteria, duplication or being pub-
lished in languages other than English. Full texts of potentially
relevant studies were then obtained and screened against the
inclusion and exclusion criteria. The reference lists of relevant
systematic reviews and included studies were hand searched.
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Data extraction
Data extraction of clinically and methodologically relevant
information was performed by a single author (SLP) and
checked by a second (A M-W). Where data were indicated
to be reported in a linked paper, we also extracted data from
that publication. The following data were extracted: first au-
thor; year of publication; study design; location; recruitment
method and when recruited, number recruited (in each cate-
gory for exposure and control group); reported characteristics;
antidepressants studied (including definition, ascertainment
and prevalent use); maternal mental disorder (including defi-
nition, ascertainment and prevalence); outcomes (including
definition, ascertainment and prevalence); other treatments;
and results (including numbers analysed). For the
neurodevelopmental outcomes, we extracted outcome data at
the last time point in the study.
Quality appraisal
We modified the Newcastle Ottawa Scale (NOS) to assess
the quality of included studies (Reeves et al. 2008). The
NOS has eight items split into three dimensions: selection,
comparability and outcome/exposure that is dependent on
the study type—outcome (cohort studies)/exposure (case-
control studies). A point rating is used with one point max-
imum for each item except for the comparability section,
which allows a two-point allocation for factors deemed
important to the review question. For the comparability
section of low birth weight studies, we allocated one point
if the study had adjusted for depression/anxiety severity
during pregnancy, and one point if it had adjusted for at
least two of the following factors: (1) other psychoactive
drug use during pregnancy, (2) smoking during pregnancy
and (3) drinking during pregnancy. For the comparability
section of the neurodevelopmental and neurobehavioural
outcome studies, we allocated half a point if the study
had adjusted/otherwise controlled for depression/anxiety
severity during pregnancy, half a point if they had adjusted
for depression severity measured at any point after deliv-
ery, half a point if they had adjusted for socio-economic
status or position (measured in income, education, area
deprivation, individual deprivation, home-ownership, etc.
either pre- or post-natally) and half a point if they had
adjusted/controlled for at least two of the following fac-
tors: (1) other psychoactive drug use during pregnancy,
(2) smoking in pregnancy, (3) drinking during pregnancy,
(4) intrauterine growth restriction / preterm delivery / ges-
tational age at delivery / small for gestational age, (5) birth
difficulties, (6) maternal age and sex of the child, (7) child
second-hand smoke exposure or other environmental pol-
lution exposure, (8) child injury, (9) paternal/partner psy-
chiatric disorder or symptoms, (10) further antidepressant
exposure through breastfeeding, (11) breastfeeding and
(12) maternal and/or paternal IQ. We compiled this list of
factors potentially related to the outcomes of interest by a
brief literature review. We weighted depression or anxiety
severity more highly than other factors in the comparability
section because a failure to account for maternal depres-
sion in non-exposed groups has been the limitation of pre-
vious reviews. For the outcome section, we removed the
second item ‘Was follow-up long enough for outcomes to
occur?’ as this formed part of our inclusion criteria. The
total score for our modified scale was 8, and we considered
a score ≥ 6 that adjusted for severity of pre- and/or post-
natal depression/anxiety to be of a lower risk of bias, and
all other studies to have a higher risk of bias.
Data transformation
Sample characteristics
Not all data was reported in the format we required to assess
prevalence and between-group differences in sample charac-
teristics. Where possible, we calculated the clinical and demo-
graphic characteristics of the sample and each exposure group
and tested for differences in those characteristics.
Outcomes
Many of the included studies compared outcomes from each of
the groups of interest in this review: ‘depressed, exposed’ and
‘depressed, non-exposed’ to a third (non-depressed, non-ex-
posed) group which was not of interest to this review. In these
cases, we re-calculated the difference between the depressed,
exposed and depressed, non-exposed groups. We did not ex-
tract estimates where the data for the non-depressed, non-
exposed group could not be separated out. To standardise the
low birth weight outcomes, we computed the log odds ratio and
its standard error from odds ratios/hazard ratios (computed
from proportions if necessary) and their variance. One study
(Oberlander et al. 2006) reported mean difference in incidence
of low birth weight of a propensity-score matched sample but
not the absolute incidence rate. In this case, we assumed that
the overall incidence rate of the exposed group was similar to
that reported for the exposed group in the non-propensity
matched sample and used this to calculate the log odds ratio.
Computing the z-statistic from the mean and confidence inter-
val reported resulted in a corresponding P value of 0.011,
which was similar to the P = 0.02 reported for the estimate of
the mean difference in the matched sample, indicating our as-
sumption was reasonable. For the neurodevelopmental out-
comes, we standardised binary outcomes as reported above,
and computed the standardised mean difference (effect size)
from any continuous outcomes where possible.
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Data synthesis
Narrative synthesis
We report a narrative synthesis of evidence and present
standardised results.
Meta-analysis
We planned to conduct meta-analyses of similar studies with
similar outcomes that we had assessed as having a lower risk
of bias (see BQuality appraisal^ section). We did not perform
any meta-analyses because no studies examining low birth
weight met these criteria, and the two studies examining later
outcomes that did meet the criteria examined different
outcomes.
Results
A total of 8708 records were retrieved, of which 88 full-text
articles were assessed for eligibility, and 11 were included in
the review: four cohort studies reporting a low birth weight
ou tcome and seven cohor t s tud ie s r epo r t ing a
neurodevelopmental outcome (Fig. 1).
Maternal antidepressant use in pregnancy and offspring’s
LBW
Extracted study characteristics, analyses and reported re-
sults are presented in Online Resource Tables S1a and S1b.
There were two cohorts assembled from registries and data
linkage from Canada (Oberlander et al. 2006) and
Denmark (Jensen et al. 2013) and two prospective cohorts
that recruited in the Netherlands (El Marroun et al. 2012)
and Norway (Nordeng et al. 2012). All women were stud-
ied between 1996 and 2006. All studies excluded multiple
births.
Exposure
All four studies examined selective serotonin reuptake in-
hibitors (SSRIs) and two also included other classes of
antidepressants: one that reported specific SSRI exposure
(fluoxetine, citalopram/escitalopram, paroxetine, sertraline
and fluvoxamine), also included tricyclic antidepressants
(TCAs) and other antidepressants (Nordeng et al. 2012);
the other examined SSRIs and newer and older antidepres-
sants without specifying them (Jensen et al. 2013). One
study excluded venlafaxine (a serotonin-norepinephrine re-
uptake inhibitor, SNRI) because it was only used in com-
bination with other non-SSRIs in the study population
(Oberlander et al. 2006). The other did not specify which
SSRIs were studied (El Marroun et al. 2012). Online
Resource Table S1a.
The two data linkage studies ascertained exposure by
redeemed prescriptions: the two prospective cohorts by
self-reported use. Three studies, one register-based
(Jensen et al. 2013) and two self-reported (El Marroun
et al. 2012; Nordeng et al. 2012), considered the exposure
period of the entire pregnancy but the Canadian register-
based study as filling a prescription at least 49 days after
the date of conception (Oberlander et al. 2006). Despite
this restriction, the prevalence of antidepressant use in the
entire cohort was much higher in the Canadian register-
based study (2.3% in 1998 rising to 5.0% in 2001)
(Oberlander et al. 2006) compared with 1.1 to 1.3% in
the other three studies. Non-exposure in three studies was
classified as no prescription redemption or use during
pregnancy (El Marroun et al. 2012; Jensen et al. 2013;
Oberlander et al. 2006); in a fourth study, the non-
exposed group consisted of women who had used an AD
in the 6 months prior to pregnancy but not during pregnan-
cy (Nordeng et al. 2012).
Maternal mental health
No study examined anxiety. The presence of depression
diagnostic codes in the medical record was used to define
both exposed and non-exposed groups in the two data link-
age studies: one covering the pregnancy period and the
previous year (14% prevalence in whole cohort)
(Oberlander et al. 2006) and one during the pregnancy only
(0.6% prevalence) (Jensen et al. 2013). Thresholds of self-
reported depressive symptoms on scales were used to indi-
cate disorder in the two prospective cohorts: one a score of
more than 2 on the Hopkins Symptom Checklist-5 (SCL-5)
at 17 weeks gestation (6.5% prevalence) (Nordeng et al.
2012) and one a score of more than 0.75 on the 6-item
depression scale of the Brief Symptom Inventory at an
average 20.6 weeks gestation (prevalence not reported)
(El Marroun et al. 2012). In these two studies, the scales
were used to classify women in the non-exposed group, but
not in the exposed group. None of the studies provided
information on other treatments provided in either group.
Online Resource Table S1a.
Outcome
Low birth weight was defined as < 10th percentile for ges-
tational age in the two data linkage studies (Jensen et al.
2013; Oberlander et al. 2006). In the other two prospective
cohorts (El Marroun et al. 2012; Nordeng et al. 2012), low
birth weight was defined as smaller than 2500 g, but both
studies adjusted for gestational age. All four studies
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ascertained birth weight from medical records. Online
Resource Table S1a.
Characteristics of included participants
One study (Jensen et al. 2013) did not report the
women’s characteristics in mutually exclusive exposure
groups. There were between-exposure group differences
in key socio-demographic features in each of the other
three studies. In an unadjusted study (Oberlander et al.
2006) reporting few demographic data, exposed women
were older, had more prenatal healthcare visits and were
more likely to have subsidised prescriptions (an indicator
of disadvantage); women were matched on these (and
other) characteristics in the propensity-matched sample
from this cohort. Exposed women in one study
(Nordeng et al. 2012) were more likely to have less
education and less likely to be married (indicators of
disadvantage), were more likely to smoke and have been
hospitalised during pregnancy. Conversely, in the Dutch
study (El Marroun et al. 2012), exposed women were
older and more likely to be Dutch but had more markers
of advantage compared to the non-exposed group, having
higher levels of education and income. Online Resource
Table S1b.
Severity of mental health problems
Severity of depressive symptoms was reported as higher in the
exposed group in one study (Nordeng et al. 2012) and higher
in the non-exposed group in another (El Marroun et al. 2012).
One study in which women in both groups had diagnoses did
not present further data on symptom severity (Jensen et al.
2013). The fourth study indicated that the exposed group
had more psychiatric health service use, but did not present
symptom severity data (Oberlander et al. 2006). Online
Resource Table S1b.
Citation identified through searching 
electronic databases (n=8684):
MEDLINE (n=7342) 
Cochrane (n=893) 
PsycINFO (n=65) 
Pubmed (n=108) 
EMBASE (n=276)
+
Articles identified by searching the 
references of existing systematic reviews and 
included articles (n=24)
Citation excluded (n=8620):
Duplicates, not relevant topic and 
conferences (n=8565)
Not empirical studies (n=41)
Not English (n=5)
Case studies and case reports (n=9)
Some studies were excluded on more than 
one criterion.
Titles /abstracts of citations screened
(n=8708)
Full text could not be obtained (n=1)
Conference abstracts (n=6)
Summary of other study, which is already 
included in the review (n=1) 
Inappropriate participant population (IP) 
(n=2) 
Inappropriate comparator (IC) (n=40) 
Inappropriate outcome (IO) (n=3)
Inappropriate study design (ISD) (n=5)
IP+IO+IC (n=1) 
IP+IC (n=2) 
IO+ IC (n=15)
The study includes required outcome, but 
doesn't provide relevant data (n=1)
Full-text articles assessed for eligibility
(n=88)
Studies met inclusion criteria (n=11):
Low birth weight (n=4)
Neurodevelopment (n=7)
•
•
Fig. 1 Flowchart for selection of
studies included in the systematic
review
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Analysis and adjustments
Only one study adjusted their regression analysis for the se-
verity of depressive symptoms (Nordeng et al. 2012), and one
other undertook propensity matching that included depressive
history as noted from health service records (Oberlander et al.
2006). Three of the studies adjusted for smoking during preg-
nancy (El Marroun et al. 2012; Jensen et al. 2013; Nordeng
et al. 2012), and one also for maternal drinking during preg-
nancy (El Marroun et al. 2012). Two studies adjusted for other
drug exposures: use of antiepileptics, antipsychotics, other
medicine (Jensen et al. 2013) and benzodiazepines (El
Marroun et al. 2012). One study used two methods of analysis
(Oberlander et al. 2006). In the first, they drew propensity
score-matched samples, matching on some socio-
demographic factors, mental health including service use,
TCAs and antipsychotic prescriptions, but not smoking or
drinking during pregnancy. It was unclear how this
propensity-matched sample was analysed. These authors also
reported an unadjusted estimate analysing the whole cohort.
Women using non-SSRI antidepressants, benzodiazepines
and antipsychotics were excluded from the unadjusted analy-
sis. The two studies reporting low birth weight as an outcome
adjusted for gestational age (El Marroun et al. 2012; Nordeng
et al. 2012). Online Resource Table S1b.
Quality assessment
All the studies scored between 5 and 6 out of 8 on the mod-
ified NOS quality assessment scale for cohort studies (Online
Resource Table S2), but none met our criteria for lower risk of
bias. All studies scored relatively highly on the selection sec-
tion and outcome criteria, reflective of study designs that were
broadly representative of pregnant women, selected all wom-
en using the same method and had an outcome that was
ascertained using routine records. No study scored the maxi-
mum two points on the section ‘Assessing comparability of
the exposure groups’ because none controlled for all the fac-
tors we deemed necessary to be comparable between the ex-
posed and non-exposed groups. One study reporting two dif-
ferent analysis samples (Oberlander et al. 2006) scored zero
on the comparability section.
Results
We present standardised effect ratios on the log odds ratio
scale (Table 1). The study that controlled for depressive symp-
toms (Nordeng et al. 2012) did not report a difference in LBW
between exposure groups. The large unadjusted study
(Oberlander et al. 2006) and an adjusted study (El Marroun
et al. 2014) also reported finding no evidence of effect. Two
studies (Jensen et al. 2013; Oberlander et al. 2006) indicated
statistically significant effect ratios, but although one matched
exposure groups on psychiatric-related health service use
(Oberlander et al. 2006), neither controlled for depression
severity.
Maternal antidepressant use in pregnancy and offspring’s
neurodevelopmental and neurobehavioural outcomes
Extracted study characteristics, analyses and reported results
are presented in Online Resource Tables S3a and S3b. Data
relating to the two groups of interest (exposed, depressed/
anxious and non-exposed) in the seven included studies were
gathered from prospective cohorts: one each from the
Netherlands (El Marroun et al. 2014) and Canada (Nulman
et al. 2012), three from the USA (Casper et al. 2003; Santucci
et al. 2014; Suri et al. 2011) and two using data from the
Danish National Birth Cohort (Pedersen et al. 2010, 2013).
Analysed sample sizes ranged from 44 to 604 (N = 31 to 294
exposed, N = 13 to 376 non-exposed), with median sample
sizes of N = 69 exposed and N = 54 non-exposed.
Exposure
Two studies investigated SSRIs (Casper et al. 2003; El
Marroun et al. 2014); two examined SSRIs and venlafaxine
(Nulman et al. 2012; Santucci et al. 2014); two examined
SSRIs, TCAs and other antidepressants or combinations
(Pedersen et al. 2010, 2013); and one did not specify the type
of antidepressants but found the majority exposed to sertraline
and fluoxetine (Suri et al. 2011). The exposure period was
defined as ‘any use in pregnancy’ by six studies and as use
in > 50% of the pregnancy in one (Suri et al. 2011). Only one
study constructed the non-exposed group from women who
discontinued antidepressants prior to pregnancy (Nulman
et al. 2012). In all studies, exposure was ascertained by self-
report. For the two studies that recruited a population cohort,
the prevalence of exposure was calculated at 0.5% (Pedersen
et al. 2010) and 1.17% (El Marroun et al. 2014). Online
Resource Table S3a.
Maternal mental health
All seven studies examined depression, or depressive symp-
toms, and none anxiety. One study used a threshold of > 0.75
on the depression scale of the Brief Symptom Inventory (ad-
ministered at 21 weeks gestation) to indicate clinically rele-
vant depressive symptoms in the unexposed group (El
Marroun et al. 2014). The exposed group was defined on
AD exposure only. The two studies using the Danish
National Cohort (Pedersen et al. 2010, 2013) reported using
responses to four questions about psychiatric disorders and
care asked at 17 and 32 weeks gestation to determine depres-
sion, but it was not clear how they were used, or whether the
same criteria were applied to the exposed group. One study
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used the women’s psychiatrist’s diagnoses of depressive epi-
sodes to define both the exposed and non-exposed groups
(Nulman et al. 2012). Three studies defined disorder in both
the exposed and non-exposed groups as diagnoses ascertained
via a structured clinical interview during pregnancy: major
depressive disorder in two (Santucci et al. 2014; Suri et al.
2011) and any DSM-IVAxis I disorder in one (Casper et al.
2003). For the two studies that recruited a population cohort,
the prevalence of disorder was calculated at 1.1% (assuming
all exposed were depressed) (Pedersen et al. 2010) and 14%
(El Marroun et al. 2014). One study reported all women also
received psychotherapy (Casper et al. 2003), another indicated
that depression in the non-exposed group was untreated
(Nulman et al. 2012) and the remaining studies did not report
whether the non-exposed group received any alternative treat-
ment for depression (El Marroun et al. 2014; Pedersen et al.
2010, 2013; Santucci et al. 2014; Suri et al. 2011). Online
Resource Table S3a.
Outcomes
The median number of outcomes in a study was 9 (min N = 5,
max N = 15). Many of the multiple outcomes were due to
analysing estimates from instrument subscales. Five studies
measured at least one outcome of abnormal development as a
threshold of a measurement scale: pervasive development
problems (El Marroun et al. 2014), behaviour (Nulman
et al. 2012; Pedersen et al. 2013), behavioural development
(Santucci et al. 2014), developmental milestones (Pedersen
et al. 2010) and attention deficit hyperactivity disorder
(ADHD) and comorbid disorders (Nulman et al. 2012). The
remaining outcomes were measured as mean scores on a scale
that could be broadly categorised as follows: autistic symp-
toms and specific autistic symptoms (El Marroun et al. 2014),
behaviour (Nulman et al. 2012; Pedersen et al. 2013), IQ
(Nulman et al. 2012), ADHD and comorbid disorders
(Nulman et al. 2012), neonate behaviour (Suri et al. 2011),
mental development (Casper et al. 2003; Santucci et al.
2014), psychomotor development (Casper et al. 2003;
Santucci et al. 2014), motor quality (Casper et al. 2003) and
behavioural development (Casper et al. 2003). Fifty percent
(N = 34) of the outcomes were assessed by an independent
rater such as a psychologist, and 50% by a parent (usually the
mother) scoring the child on a scale. Five studies measured
some or all of the outcomes at multiple time points (El
Marroun et al. 2014; Pedersen et al. 2010; Santucci et al.
2014; Suri et al. 2011). The oldest age of assessment in any
one study ranged from 6–8 weeks to 6 years 11 months.
Online Resource Table S3a.
Characteristics of included participants
Most studies reported some differences in characteristics
between exposure groups. One (El Marroun et al. 2014)
reported that exposed women were older, had more educa-
tion, were more likely to be Dutch, were more likely to
have drunk alcohol during pregnancy and were more likely
having given birth to girls than non-exposed women.
Another (Pedersen et al. 2013) reported no differences on
key characteristics but we could not ascertain whether
there were differences in maternal age and caffeine intake
as data were incompletely reported. Children in the non-
exposed group were older at the time of assessment in one
study (Nulman et al. 2012), and had a longer mean gesta-
tional age in another (Suri et al. 2011). One study
(Pedersen et al. 2010) reported that exposed women were
older and had higher educational attainment; however, the
data presented included those for whom the child’s out-
come was missing so we could not tell whether this was
the case for the analysed sample. Women in the exposed
group in one study (Santucci et al. 2014) were more likely
to be White, have completed university and be married or
cohabiting, and exposed children in another (Casper et al.
2003) were more likely to have a mother taking an SSRI
while breastfeeding and had lower APGAR scores than
non-exposed children. Online Resource Table S3b.
Table 1 Results for low birth weight
Study, antidepressants studied Effect ratio 95% CI N Adjustments/exclusions/stratification
Nordeng et al. (2012), SSRI 0.67 0.29, 1.52 1747 a, b, d, h, g, j, i, l
Jensen et al. (2013), AD 1.42 1.16, 1.73 3966 c, d, f, g, o
El Marroun et al. (2012), SSRI 1.72 0.73, 4.07 669 c, d, e, f, g, h, j, k, m
Oberlander et al. (2006), non-PS SSRI 1.05 0.87, 1.28 15,685 f
Oberlander et al. (2006), PS SSRI 1.69 1.14, 2.52 1622 c, f, p
Estimates in bold are statistically significant. Effect ratio is on log odds scale. a. Maternal mental health pre-birth, b. maternal age, c. socio-economic
status, d. smoking in pregnancy, e. alcohol in pregnancy, f. other psychoactive drug and/ormedication use during pregnancy, g. sex of child, h. gestational
age, i. illness/disease during pregnancy, j. parity, k. ethnicity, l. folic acid use, m. body mass index, o. calendar year of delivery, p. psychiatric-related
health service use
PS propensity score-matched sample, SSRI selective serotonin reuptake inhibitors, AD antidepressant, CI confidence interval
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Severity of mental health problems
Severity of prenatal depressive symptoms was reported as
higher in the non-exposed group in three studies (El
Marroun et al. 2014; Pedersen et al. 2010, 2013) and higher
in both the non-exposed group and the women exposed to
SSRIs, versus the women exposed to venlafaxine, in another
(Nulman et al. 2012). Three studies (Casper et al. 2003;
Santucci et al. 2014; Suri et al. 2011) did not find a statistically
significant difference in severity symptoms between exposure
groups. Online Resource Table S3b.
Severity of depressive symptoms measured at some point
after delivery was reported as higher in the non-exposed group
in two studies (El Marroun et al. 2014; Pedersen et al. 2010).
No between-group differences in symptom severity were de-
tected in two studies (Nulman et al. 2012; Suri et al. 2011),
and differences were not measured or reported in three
(Casper et al. 2003; Pedersen et al. 2013; Santucci et al.
2014). One study (Pedersen et al. 2013) noted that they found
no difference in the proportion of women who met DSM-IV
criteria for major depression, but women in the exposed group
were more likely to be on medical treatment for depression
since the delivery.
Analysis and adjustments
Three studies adjusted some analyses for depressive symp-
toms at some time after the child was born (El Marroun
et al. 2014; Pedersen et al. 2010, 2013), and one for symptoms
both during pregnancy and at some time after birth (Suri et al.
2011). Smoking during pregnancy and markers of socio-
economic status were adjusted for in two studies (El
Marroun et al. 2014; Pedersen et al. 2013) and results stratified
by maternal smoking and drinking during pregnancy in a third
(Pedersen et al. 2010). Three studies adjusted for maternal age
(El Marroun et al. 2014; Pedersen et al. 2010, 2013), three the
sex of the child (El Marroun et al. 2014; Pedersen et al. 2010,
2013) and two gestational age at birth (El Marroun et al. 2014;
Suri et al. 2011). Five studies excluded women taking other
psychotropic or teratogenic medications during pregnancy
from the analysis (Nulman et al. 2012; Pedersen et al. 2010;
Santucci et al. 2014; Suri et al. 2011), one did not adjust the
analysis for the higher usage of benzodiazapines in the ex-
posed group (El Marroun et al. 2014) and one did not report
or adjust for other medication during pregnancy (Casper et al.
2003). One study stratified results by exposure window and
type of antidepressant (Pedersen et al. 2010). Most studies
reported using multivariable linear (El Marroun et al. 2014;
Pedersen et al. 2010, 2013) or logistic ( Pedersen et al. 2010,
2013) regression or analysis of covariance (Casper et al. 2003;
Suri et al. 2011) to analyse outcomes, but unadjusted propor-
tions (Nulman et al. 2012; Santucci et al. 2014) and
unadjusted means (Casper et al. 2003; Santucci et al. 2014)
were also reported. Online Resource Table S3b.
Quality assessment
Only two studies met our criteria for lower risk of bias (El
Marroun et al. 2014; Suri et al. 2011) (Online Resource
Table S4). Only one study (Suri et al. 2011) adjusted estimates
for pregnancy depression severity, and four for post-delivery
severity (El Marroun et al. 2014; Pedersen et al. 2010, 2013;
Suri et al. 2011). Two adjusted for some marker of socio-
economic status (El Marroun et al. 2014; Pedersen et al.
2013), and these, along with two more (Pedersen et al. 2010;
Suri et al. 2011), controlled for at least another two of our pre-
defined potential confounders. Three studies (Casper et al.
2003; Nulman et al. 2012; Santucci et al. 2014) did not adjust
their analyses for any potential confounders although one ex-
cluded users of benzodiazepines or any US FDA pregnancy
class D or X drugs (Santucci et al. 2014) and another excluded
users of known teratogens and polytherapy for depression
(Nulman et al. 2012). Only one study (Suri et al. 2011) scored
the maximum two points on the ‘Outcome’ section, with
others losing points mainly because child outcomes were re-
ported by the parents and not an independent observer, or the
method of ascertainment was not described.
Results
Results are reported grouped by child age (Tables 2, 3, 4 and 5).
Neonate behaviour
The results from one study with a lower risk of bias (Suri et al.
2011) indicated few differences in neonate behaviour mea-
sured by the BNBAS between exposure groups, except for a
mean score difference in habituation (Table 2). The authors
reported (in narrative) no effect by exposure group after
adjusting for gestational age at delivery, mean and maximum
HDRS (depressive symptom) scores in pregnancy and 4 and
8 weeks after delivery, and sex of the child; however, these
models also included the non-depressed, non-exposed group.
Infant and toddler development
Three studies, all with higher risk of bias, measured infant and
toddler development (Table 3). Two of the 15 measurements
made by one study (Casper et al. 2003) (BRS subscale Motor
Quality and Psychomotor development, adjusted for 5-min
APGAR score) indicated statistically significant worse devel-
opment for children age 26–173 weeks exposed to SSRIs. One
study (Pedersen et al. 2010) noted a statistically significant
difference of 13.6 days in the retrospectively reported age at
which the child first walked without support for children
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exposed to antidepressants (adjusted for a range of con-
founders) and a larger difference (28.9 days) for women ex-
posed in the second/third trimester after stratification (for anti-
depressants overall and for SSRIs). They found no other
between-group differences in the other 10 items measured, in-
cluding after stratification for exposure window. The third
study (Santucci et al. 2014) noted no between-group differ-
ences for the seven items they measured (unadjusted analyses).
Child behavioural outcomes
None of the three studies (El Marroun et al. 2014; Nulman
et al. 2012; Pedersen et al. 2013) only one (El Marroun et al.
2014) with a lower risk of bias, reporting a total of 15 behav-
ioural outcomes, found a statistically significant difference by
exposure group (Table 4).
Child autistic symptoms
There were no differences between exposure groups in symp-
toms of autism reported by the mother on the SRS at age 6 for
the one study that reported these outcomes (El Marroun et al.
2014) (lower risk of bias) (Table 5).
ADHD and comorbid disorders
The one study (Nulman et al. 2012) (higher risk of bias) ex-
amining this outcome found a statistically significant higher
proportion of 3–7-year-old children with a clinically signifi-
cant total problems score on the Conners’ Parent Rating Scale
(parent reported, unadjusted) exposed to SSRIs, but not for the
children whowere venlafaxine-exposed (Table 5). They found
no between-group variation in the DSM total symptom scores.
Discussion
Untreated common mental disorders and symptoms during
pregnancy pose risks to offspring (Gentile 2015; Kingston
et al. 2012). Therefore, to answer a clinically relevant question,
the effect of in utero antidepressant exposure on children should
be ascertained against the effects of common mental disorders
during pregnancy. Previous systematic reviews have been lim-
ited by comparing exposed children with children of healthy
women. We conducted a systematic review of observational
studies examining birth weight and development outcomes for
children exposed to antidepressants in utero compared to chil-
dren of womenwith commonmental disorders, or symptoms of
common mental disorders, but no antidepressant exposure.
Despite selecting only those studies with such a control group,
few analyses were controlled for depressive symptom severity
between exposure groups, raising concerns about selection bias.
This, along with other design limitations and sources of bias,
limits the conclusions we can draw from the synthesis.
Non-exposed comparators
Only two studies out of the 11 included in our review con-
structed the non-exposed comparator group solely from wom-
en who were exposed in the months prior to pregnancy but not
during pregnancy. This situation most closely represents the
clinical problem, namely should women needing to take anti-
depressants, and considering pregnancy, discontinue them pri-
or to pregnancy, that is will the effect of not taking them
outweigh the effect of non-medically treated symptoms?
Antidepressants are not a first-line therapy for mild to moder-
ate common mental disorder, and women who never take
antidepressants may, on average, have less severe symptoms,
which potentially could exert fewer biological effects.
Table 2 Results for neonate behaviour
Study, antidepressants
studied
Child age at
testing (weeks)
Outcome Effect size 95% CI N Adjustments/exclusions/
stratification
Suri et al. (2011), NR (most exposures
sertraline and fluoxetine)
6–8 1a. Habituation 0.81 0.14, 1.48 46 g
1b. Orientation − 0.38 − 1.03, 0.27 46 g
1c. Motor − 0.43 − 1.09, 0.22 46 g
1d. Defence 0.19 − 0.46, 0.84 46 g
1e. Range of state − 0.11 − 0.76, 0.54 46 g
1f. Regulation of state 0.17 − 0.48, 0.82 46 g
1g. Autonomic stability − 0.27 − 0.92, 0.38 46 g
h. Reflexes 0.30 − 0.35, 0.95 46 g
Estimates in bold are statistically significant. a.Maternal mental health pre-birth, b. maternal mental health at some point after delivery, c. maternal age, d.
socio-economic status, e. smoking in pregnancy, f. alcohol in pregnancy, g. other psychoactive drug and/or medication use during pregnancy, h. sex of
child, i. gestational age, j. age of child at testing, k. APGAR scores, l. breastfeeding, m. problems during pregnancy, n. mother-child connection, o.
postnatal difficulties, p. ethnicity, q. exposure window
NR not reported, CI confidence interval
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Table 3 Results for infant and toddler development
Study, antidepressants
studied
Child age at testing (weeks) Outcome Effect ratio 95% CI N Adjustments/exclusions/
stratification
Santucci et al. (2014), SSRI
and venlafaxine
12 1b. BRS subscale—attention/arousal 0.54 0.14, 2.09 53 g
78 1a. Behavioural rating scale—total score 2.38 0.25, 23.2 37 g
1c. BRS subscale—orientation/engagement 3.00 0.32, 28.4 37 g
1d. BRS subscale—emotional regulation 1.41 0.30, 6.68 37 g
1e. BRS subscale—motor quality 2.29 0.49, 10.6 37 g
Pedersen et al. (2010), AD 78 1a. Gross-motor—going up stairs with support 1.00 0.49, 2.03 478 b, c, e, f, g, h, j, l, m, n, o, q
1c. Fine motor—taking off socks and shoes when asked to 1.10 0.71, 1.71 483 b, c, e, f, g, h, j, l, m, n, o, q
1d. Fine motor—drinking from ordinary cup without help 3.40 0.67, 17.3 482 b, c, e, f, g, h, j, l, m, n, o, q
1e. Attention—being occupied alone for ≥ 15 min 1.20 0.75, 1.93 486 b, c, e, f, g, h, j, l, m, n, o, q
1f. Cognition—bringing things when told to 0.80 0.27, 2.37 478 b, c, e, f, g, h, j, l, m, n, o, q
1g. Cognition—making marks on table or paper 1.30 0.57, 2.97 490 b, c, e, f, g, h, j, l, m, n, o, q
1h. Cognition—aligning picture correctly 1.00 0.69, 1.45 460 b, c, e, f, g, h, j, l, m, n, o, q
1i. Language—using word-like sounds to tell what s/he wants 1.40 0.61, 3.21 492 b, c, e, f, g, h, j, l, m, n, o, q
1j. Language—mentioning > 25 names of different things 1.70 0.94, 3.07 492 b, c, e, f, g, h, j, l, m, n, o, q
1k. Language—using 2-word sentences 1.20 0.83, 1.74 467 b, c, e, f, g, h, j, l, m, n, o, q
1l. Failed ≥ 1 milestone 2.10 0.93, 4.75 492 b, c, e, f, g, h, j, l, m, n, o, q
Effect size
Santucci et al. (2014), SSRI and venlafaxine 78 2. Mental development − 0.16 − 0.86, 0.55 38 g
Santucci et al. (2014), SSRI and venlafaxine 78 3. Psychomotor development − 0.64 − 1.35, 0.08 38 g
Pedersen et al. (2010), AD – 1b. Age at which child walked without support (difference in days) 13.6 4.0, 23.3 NR b, c, e, f, g, h, j, l, m, n, o, q
Pedersen et al. (2010), SSRI – 15.2 4.6, 25.9 NR b, c, e, f, g, h, j, l, m, n, o, q
Pedersen et al. (2010), TCA – 11.9 − 12.0, 35.8 NR b, c, e, f, g, h, j, l, m, n, o, q
Other metric
Casper et al. (2003), SSRI 26–173 1a. Behavioural rating scale F = 2.57, P = 0.12 44 k
1b. BRS subscale—attention/arousal F = 1.2, P = 0.31 44 k
1c. BRS subscale—orientation/engagement F = 0.02, P = 0.88 44 k
1d. BRS subscale—emotional regulation F = 0.07, P = 0.79 44 k
1e. BRS subscale—motor quality F = 4.02, P = 0.05 44 k
Casper et al. (2003), SSRI 26–173 3. Mental development F = 2.12, P = 0.15 44 k
2a. Gross motor movement F = 2.01, P = 0.17 44 k
2b. Fine motor movement F = 2.22, P = 0.15 44 k
2c. Control of movement F = 0.55, P = 0.46 44 k
2d. Tremulousness F = 3.37, P = 0.08 44 k
2e. Slow and delayed movement F = 0.06, P = 0.81 44 k
2f. Frenetic movement F = 2.14, P = 0.15 44 k
2g. Hypertonicity F = 0.74, P = 0.40 44 k
2h. Hypotonicity F = 0.05, P = 0.83 44 k
4. Psychomotor development F = 5.55, P = 0.02 44 k
Estimates in bold are statistically significant. Effect ratio is on log odds scale. a. Maternal mental health pre-birth, b. maternal mental health at some point after delivery, c. maternal age, d. socio-economic
status, e. smoking in pregnancy, f. alcohol in pregnancy, g. other psychoactive drug and/or medication use during pregnancy, h. sex of child, i. gestational age, j. age of child at testing, k. APGAR scores, l.
breastfeeding, m. problems during pregnancy, n. mother-child connection, o. postnatal difficulties, p. ethnicity, q. exposure window
SSRI selective serotonin reuptake inhibitors, AD antidepressants generally, CI confidence interval
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Alternatively, women could refuse medical treatment for a
moderate to severe episode. Constructing the comparison
group from a non-antidepressants-using cohort is therefore
of limited value unless analyses account for any potential dif-
ference in symptom severity. We acknowledge that a defini-
tive controlled trial randomising women to either discontinue
antidepressants prior to conception or continue them through
pregnancy is both unethical and largely unfeasible. We con-
sider, however, that much more could be done to attempt to
limit differences and control for differential effects, and also
believe that a preference trial variant (Torgerson and Sibbald
1998) may be both desirable and possible to conduct in the
maternal setting.
Outcomes: low birth weight
We found only limited evidence of lower birth weight in chil-
dren exposed to antidepressants in two studies which had a
higher risk of bias and did not control for depressive symptom
severity. These studies were both retrospective: one a data
linkage study and one a register-based cohort. In an older
review, Ross et al. (2013) examined a similar question, finding
no evidence of effect. Only one of our included studies over-
lapped those reviewed by Ross et al. due to a variation in
exclusion criteria and dates searched. Together, these synthe-
ses indicate that there is currently little evidence to indicate
that antidepressant use in pregnancy causes children to be
born with lower birth weight accounting for gestational age.
Depression itself has been associated with LBW (Grote et al.
2010), but basic science studies also confirm the cross placen-
tal passage of SSRIs and the subsequent effects on vascular-
isation which could result in LBW (Wessler et al. 2007).
Therefore, future studies should continue to analyse the link.
Outcomes: neurodevelopment and neurobehaviour
Out of 59 child neurodevelopmental effect estimates we exam-
ined, only five (8.5%) showed evidence of a statistically signif-
icant effect, which could have been due to type I error, or chance
false positive. All three of the studies reporting a statistically
significant effect were assessed as having a higher risk of bias.
The single study of neonate behaviour was of lower risk of bias
and found an effect in only one out of eight outcomes (12.5%).
While all the studies were of a prospective design, many were
very small and likely underpowered. Even in the case of the
studies demonstrating significant effects, their clinical impor-
tance can be questioned. For example, there is a large normal
range of time it takes for a child to walk unsupported, within
which a difference of 13.6 days may be a reflection of this
variation rather than an increase in the delay of onset of walking.
The results should thus be interpreted with caution. Importantly,
serotonin has diverse functions in utero to guide foetal develop-
ment (Bourke et al. 2014). As documented in animal models,T
a
b
le
4
R
es
u
lt
s
fo
r
ch
il
d
b
eh
av
io
u
ra
l
o
u
tc
o
m
es
S
tu
d
y,
an
ti
d
ep
re
ss
an
ts
st
u
d
ie
d
C
h
il
d
ag
e
at
te
st
in
g
O
u
tc
o
m
e
E
ff
ec
t
ra
ti
o
9
5
%
C
I
N
A
d
ju
st
m
en
ts
/e
xc
lu
si
o
n
s/
st
ra
ti
fi
ca
ti
o
n
E
l
M
ar
ro
u
n
et
al
.
(2
0
1
2
),
S
S
R
I
1
8
m
o
n
th
s,
3
an
d
6
y
ea
rs
1
.
P
er
v
as
iv
e
D
ev
el
o
p
m
en
ta
l
P
ro
b
le
m
s
1
.3
3
0
.7
1
,
2
.5
0
4
4
5
c,
d
,
e,
h
,
i
N
u
lm
an
et
al
.
(2
0
1
2
),
v
en
la
fa
x
in
e
3
–
7
y
ea
rs
2
a.
A
b
n
o
rm
al
T
o
ta
l
D
if
fi
cu
lt
ie
s
1
.3
4
0
.3
6
,
5
.0
2
11
6
g
N
u
lm
an
et
al
.
( 2
0
1
2
)
S
S
R
I
1
.5
9
0
.4
4
,
5
.7
6
11
6
g
P
ed
er
se
n
et
al
.
(2
0
1
3
),
A
D
4
–
5
y
ea
rs
1
a.
A
b
n
o
rm
al
T
o
ta
l
D
if
fi
cu
lt
ie
s
1
.3
0
0
.4
1
,
4
.1
1
2
2
5
c,
d
,
e,
f,
g
,
h
1
b
.
A
b
n
o
rm
al
E
m
o
ti
o
n
al
su
b
sc
al
e
1
.6
0
0
.4
8
,
5
.3
4
2
2
5
c,
d
,
e,
f,
g
,
h
1
c.
A
b
n
o
rm
al
C
o
n
d
u
ct
su
b
sc
al
e
0
.6
0
0
.2
9
,
1
.2
5
2
2
5
c,
d
,
e,
f,
g
,
h
1
d
.
A
b
n
o
rm
al
H
y
p
er
ac
ti
v
it
y
su
b
sc
al
e
1
.8
0
0
.5
9
,
5
.5
0
2
2
5
c,
d
,
e,
f,
g
,
h
1
e.
A
b
n
o
rm
al
P
ee
r
su
b
sc
al
e
0
.9
0
0
.1
8
,
4
.4
1
2
2
5
c,
d
,
e,
f,
g
,
h
1
f.
A
b
n
o
rm
al
P
ro
so
ci
al
su
b
sc
al
e
0
.5
0
0
.1
7
,
1
.4
6
2
2
5
c,
d
,
e,
f,
g
,
h
E
ff
ec
t
si
ze
P
ed
er
se
n
et
al
.
( 2
0
1
3
),
A
D
4
–
5
y
ea
rs
2
a.
T
o
ta
l
D
if
fi
cu
lt
ie
s
sc
o
re
−
0
.7
0
−
1
.8
0
,
0
.4
0
2
2
5
c,
d
,
e,
f,
g
,
h
2
b
.
E
m
o
ti
o
n
al
su
b
sc
al
e
sc
o
re
−
0
.3
0
−
0
.7
0
,
0
.1
0
2
2
5
c,
d
,
e,
f,
g
,
h
2
c.
C
o
n
d
u
ct
su
b
sc
al
e
sc
o
re
−
0
.1
0
−
0
.5
0
,
0
.3
0
2
2
5
c,
d
,
e,
f,
g
,
h
2
d
.
H
y
p
er
ac
ti
v
it
y
su
b
sc
al
e
sc
o
re
−
0
.2
0
−
0
.7
0
,
0
.4
0
2
2
5
c,
d
,
e,
f,
g
,
h
2
e.
P
ee
r
su
b
sc
al
e
sc
o
re
−
0
.1
0
−
0
.4
0
,
0
.2
0
2
2
5
c,
d
,
e,
f,
g
,
h
2
f.
P
ro
so
ci
al
su
b
sc
al
e
sc
o
re
0
.1
0
−
0
.4
0
,
0
.5
0
2
2
5
c,
d
,
e,
f,
g
,
h
E
st
im
at
es
in
b
o
ld
ar
e
st
at
is
ti
ca
ll
y
si
g
n
if
ic
an
t.
E
ff
ec
t
ra
ti
o
is
o
n
lo
g
o
d
d
s
sc
al
e.
a.
M
at
er
n
al
m
en
ta
l
h
ea
lt
h
p
re
-b
ir
th
,
b
.
m
at
er
n
al
m
en
ta
l
h
ea
lt
h
at
so
m
e
p
o
in
t
af
te
r
d
el
iv
er
y,
c.
m
at
er
n
al
ag
e,
d
.
so
ci
o
-e
co
n
o
m
ic
st
at
u
s,
e.
sm
o
k
in
g
in
p
re
g
n
an
cy
,
f.
al
co
h
o
l
in
p
re
g
n
an
cy
,g
.
o
th
er
p
sy
ch
o
ac
ti
v
e
d
ru
g
an
d
/o
r
m
ed
ic
at
io
n
u
se
d
u
ri
n
g
p
re
g
n
an
cy
,h
.
se
x
o
f
ch
il
d
,i
.
g
es
ta
ti
o
n
al
ag
e,
j.
ag
e
o
f
ch
il
d
at
te
st
in
g
,k
.
A
P
G
A
R
sc
o
re
s,
l.
b
re
as
tf
ee
d
in
g
,
m
.
p
ro
b
le
m
s
d
u
ri
n
g
p
re
g
n
an
cy
,
n
.
m
o
th
er
-c
h
il
d
co
n
n
ec
ti
o
n
,
o
.
p
o
st
n
at
al
d
if
fi
cu
lt
ie
s,
p
.
et
h
n
ic
it
y,
q
.
ex
p
o
su
re
w
in
d
o
w
S
S
R
I
se
le
ct
iv
e
se
ro
to
n
in
re
u
p
ta
k
e
in
h
ib
it
o
rs
,
A
D
an
ti
d
ep
re
ss
an
ts
g
en
er
al
ly
,
C
I
co
n
fi
d
en
ce
in
te
rv
al
A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring’s outcomes 137
there are also natural processes involving a switch from a pla-
cental serotonin to endogenous foetal serotonin (Bonnin et al.
2011) during development, and thus, any disruptions during
critical times of foetal development may potentially have long-
term effects particularly for the foetal brain. Therefore, future
studies should continue the exploration of the effect of antide-
pressants on neurodevelopmental outcomes.
Future research
To overcome the limitations we have uncovered in our review,
our main recommendation is that a study design standard is
developed. This could be achieved by any range of consensus
methods such as those used to generate core outcome sets
(Gargon et al. 2014). We recommend this because studies
examining child outcomes are typically small and outcomes
rare, yet they are currently too dissimilar and/or biased to pool
in meta-analyses. Based on the findings of our review, areas to
consider include ascertainment, measurement and reporting of
exposure, disorder and outcomes, timing of exposure, other
treatments, and collection of socio-demographic data and oth-
er factors that could potentially confound any particular out-
come (Bandoli et al. 2016).
In the meantime, we recommend that researchers continu-
ing to analyse data construct two separate non-exposed com-
parator groups. The first is ascertained in the same way to the
exposed group and varying only in that women are exposed to
antidepressants in the months prior to pregnancy but have
discontinued by the washout period (defined by the exposure
window on the outcome) prior to conception. The second
group is similarly ascertained but women have no
antidepressant exposure in at least the year prior to pregnancy.
Symptom severity should be measured in all groups, exposed
and non-exposed, and symptom scores adjusted for in multivar-
iate analyses. Using data about service use in place of direct
measurement of symptom severity is likely to under-ascertain
disorder severity for some women, as service use may not be
proportionate to need particularly among disadvantaged groups.
The lack of verification of accurate and comparable between-
group ascertainment is a major limitation in currently available
routine data and register-based linkage. Researchers construct-
ing comparative groups using such data should consider using
methods that minimise ascertainment bias such as matching
exposed and non-exposed women on date and timing of diag-
noses, for example, and conducting sensitivity analyses on study
assumptions. Any effects of restricting the sample in this way on
the generalisability of the study population should be carefully
reviewed. Data on relapse following discontinuation during
pregnancy are sparse and conflicting (Cohen et al. 2004, 2006;
Yonkers et al. 2011), but accurate information on relapse and its
effect is an important factor needed to balance the argument on
risk of treatment discontinuation. Relapse in any exposure group
during pregnancy should be identified, and this information
analysed along with predictors of this risk such as the number
of previous episodes and the start of current episode. The pre-
sentation of both bivariate and multivariate risk estimates would
further our understanding about the size of effects due to varia-
tion in symptom severity. The presentation of multivariate esti-
mates is also crucial to our ability to accurately synthesise stud-
ies, even if the addition of a particular covariate does not sub-
stantially change a point estimate in an individual study.
Although anxiety can be treated with antidepressants (Howard
Table 5 Results for child autistic symptoms, ADHD and comorbid disorders
Study, antidepressants studied Child age at
testing (years)
Outcome Effect size 95% CI N Adjustments/exclusions/
stratification
Child autistic symptoms
El Marroun et al. (2012), SSRI 6 2. Autistic symptoms 0.10 − 0.32, 0.52 272 b, c, d, e, h, i, p
3a. Social cognition 0.08 − 0.36, 0.52 272 b, c, d, e, h, i, p
3b. Social communication 0.12 − 0.36, 0.60 272 b, c, d, e, h, i, p
3c. Autistic mannerisms 0.08 − 0.31, 0.47 272 b, c, d, e, h, i, p
Effect ratio
Child ADHD and comorbid disorders
Nulman et al. (2012), venlafaxine 3–7 4a. Total problems 4.65 0.53, 41.1 116 g
SSRI 11.4 1.42, 91.8 116 g
Venlafaxine 4b. DSM total symptoms 0.85 0.28, 2.61 116 g
SSRI 0.85 0.28, 2.61 116 g
Estimates in bold are statistically significant. Effect ratio is on log odds scale. a. Maternal mental health pre-birth, b. maternal mental health at some point
after delivery, c. maternal age, d. socio-economic status, e. smoking in pregnancy, f. alcohol in pregnancy, g. other psychoactive drug and/or medication
use during pregnancy, h. sex of child, i. gestational age, j. age of child at testing, k. APGAR scores, l. breastfeeding, m. problems during pregnancy, n.
mother-child connection, o. postnatal difficulties, p. ethnicity, q. exposure window
SSRI selective serotonin reuptake inhibitors, CI confidence interval
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et al. 2014), we found no studies on anxiety that matched our
inclusion criteria. Further research on anxiety and its treatment
in pregnancy is urgently needed.
External generalisability
Where it could be calculated, we found variation in the prev-
alence of antidepressant use during pregnancy and in the prev-
alence of depression and depressive symptomology in whole
cohorts. These differences may reflect between-country vari-
ation in guidelines for prescribing during pregnancy, and treat-
ment success, with potential consequences for variation in
which women of different clinical and/or social characteristics
were selected into each exposure group. It could also reflect
differences in ascertainment method (self-report vs. linked
data on prescriptions) and timing of exposure windows.
Strengths and limitations
We double checked all our extracted data and risk of bias
assessments; however, only one person searched, screened
and selected studies for inclusion which may have resulted
in some studies being missed. Like others (Stang 2010), we
did not find the NOS sensitive to limitations in study de-
sign without significant alteration; the use of another tool
may have resulted in a better differentiated assessment of
study quality. Due to resource limitations, we were unable
to include articles published in languages other than
English, which may have resulted in us not including all
relevant studies.
Conclusion
We found only very limited evidence from observational stud-
ies that birth weight and child neurodevelopment and
neurobehaviour are impacted by gestational exposure to anti-
depressants. We were unable to conduct meta-analyses due to
a high risk of bias and variation in study design. Accordingly,
we cannot be certain that any effects attributed to antidepres-
sant exposure are not reflecting underlying differences in clin-
ical and social characteristics of women who continue antide-
pressants in pregnancy, compared to those who discontinue, or
those who do not take them at all. Standardising how studies
ascertain, measure and report exposures, disorders, outcomes
and other treatments would improve our ability to accurately
estimate the presence and size of effects, and ultimately pro-
vide less biased information with which to inform clinical
decision-making.
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